Life sciences company VolitionRx has secured CE mark for its Nu.Q Colorectal Cancer Screening Triage Test paving te way for its launch across the European Union (EU).

Developed in collaboration with the Hvidovre Hospital of University of Copenhagen, Nu.Q detects nucleosomic markers of cancer for an early stage detection using a series of convenient, inexpensive and accurate blood tests.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The test analyses the unique nucleosomes to ascertain the presence of the disease.

“The triage test has exhibited up to 25% efficacy in reducing colonoscopies.”

The introduction of the Nu.Q colorectal cancer screening triage test will complement the existing standard screening test, the fecal immunochemical test (FIT) widely used in colorectal cancer screening programmes.

Volition chief marketing and communications officer Louise Day said: “Being able to offer European healthcare systems a simple and easy to use blood test which can be used to triage FIT positive populations for colorectal cancer has the potential to make a significant difference in many people’s lives and to help health care systems better serve patients.

“We have identified the first wave of European countries for launch and are pleased with the progress we are making.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The triage test has been designed to identify patients who have received false positive result on their FIT test as the standard test detects blood in stool which is not substantial to confirm presence of cancer.

Application of the triage test determines applicability of colonoscopy for patients on the basis of combined test results which helps streamlining the diagnostic process as well as minimise unnecessary colonoscopies.

The triage test has exhibited up to 25% efficacy in reducing colonoscopies with 97% detection of colorectal cancer when combined with the fecal immunochemical test (FIT) score.